🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 23 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 29/09/2010 | 35,45 | 35,57 | 34,84 | 34,94 | -1,66% | 2,06% | 1.964.000 |
| 28/09/2010 | 35,98 | 36,19 | 35,37 | 35,53 | -0,45% | 2,28% | 1.547.600 |
| 27/09/2010 | 36,74 | 36,79 | 35,67 | 35,69 | -3,23% | 3,05% | 1.724.300 |
| 24/09/2010 | 36,55 | 36,95 | 36,17 | 36,88 | +2,10% | 2,13% | 1.510.500 |
| 23/09/2010 | 34,68 | 36,25 | 34,66 | 36,12 | -0,14% | 4,58% | 4.830.600 |
| 22/09/2010 | 36,19 | 37,10 | 36,04 | 36,17 | -0,14% | 2,93% | 1.727.000 |
| 21/09/2010 | 36,38 | 36,55 | 35,99 | 36,22 | -0,77% | 1,54% | 1.032.700 |
| 20/09/2010 | 36,43 | 36,71 | 36,09 | 36,50 | +0,69% | 1,70% | 1.662.400 |
| 17/09/2010 | 36,83 | 36,91 | 35,93 | 36,25 | -1,47% | 2,66% | 1.746.000 |
| 16/09/2010 | 37,00 | 37,45 | 36,56 | 36,79 | -1,21% | 2,41% | 1.269.700 |
| 15/09/2010 | 37,36 | 37,44 | 37,04 | 37,24 | -0,53% | 1,07% | 1.262.500 |
| 14/09/2010 | 36,62 | 37,55 | 36,62 | 37,44 | +1,88% | 2,54% | 1.957.600 |
| 13/09/2010 | 36,52 | 36,85 | 36,50 | 36,75 | +0,77% | 0,96% | 1.736.200 |
| 10/09/2010 | 36,08 | 36,51 | 35,83 | 36,47 | +1,62% | 1,88% | 2.603.400 |
| 09/09/2010 | 36,25 | 36,64 | 35,73 | 35,89 | -0,44% | 2,51% | 1.696.000 |
| 08/09/2010 | 35,12 | 36,08 | 34,75 | 36,05 | +2,97% | 3,79% | 4.632.500 |
| 07/09/2010 | 36,23 | 36,26 | 34,84 | 35,01 | -2,91% | 3,92% | 849.800 |
| 03/09/2010 | 35,79 | 36,08 | 35,50 | 36,06 | +1,72% | 1,62% | 808.300 |
| 02/09/2010 | 34,71 | 35,45 | 34,42 | 35,45 | +1,55% | 2,97% | 1.184.900 |
| 01/09/2010 | 33,68 | 35,06 | 33,58 | 34,91 | +4,80% | 4,39% | 1.725.500 |
| 31/08/2010 | 33,16 | 33,59 | 33,00 | 33,31 | -0,92% | 1,78% | 1.342.500 |
| 30/08/2010 | 34,32 | 34,62 | 33,61 | 33,62 | -2,41% | 2,94% | 619.800 |
| 27/08/2010 | 33,55 | 34,74 | 32,88 | 34,45 | +3,21% | 5,54% | 1.020.700 |
| 26/08/2010 | 34,49 | 34,49 | 33,30 | 33,38 | -3,19% | 3,45% | 877.100 |
| 25/08/2010 | 33,90 | 34,63 | 33,78 | 34,48 | +1,08% | 2,51% | 851.600 |
| 24/08/2010 | 34,96 | 34,96 | 34,11 | 34,11 | -3,15% | 2,43% | 972.800 |
| 23/08/2010 | 35,81 | 36,19 | 35,19 | 35,22 | -1,01% | 2,79% | 1.014.900 |
| 20/08/2010 | 35,24 | 35,74 | 34,76 | 35,58 | +0,62% | 2,78% | 893.100 |
| 19/08/2010 | 36,36 | 36,45 | 35,14 | 35,36 | -2,78% | 3,60% | 1.348.100 |
| 18/08/2010 | 36,12 | 36,75 | 35,80 | 36,37 | +0,25% | 2,63% | 875.000 |